Evidence map›Paper›PMID 41688407›Full record

ArticleACS nano2026

Drug-free Immunotherapeutic Biomimetic Nanoparticles for Treating Triple-Negative Breast Cancer.

Ofri Vizenblit, Rawan Mhajne, Assaf Zinger

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS nano, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Ofri VizenblitBioinspired Nano Engineering and Translational Therapeutics Lab, Department of Chemical Engineering, Technion-Israel Institute of Technology, Haifa 3200003, Israel.
Rawan MhajneBioinspired Nano Engineering and Translational Therapeutics Lab, Department of Chemical Engineering, Technion-Israel Institute of Technology, Haifa 3200003, Israel.
Assaf ZingerBioinspired Nano Engineering and Translational Therapeutics Lab, Department of Chemical Engineering, Technion-Israel Institute of Technology, Haifa 3200003, Israel.ORCID 0000-0001-7894-486X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tumor-associated macrophages (TAMs) are key drivers of tumor progression, metastasis, and immune evasion in triple-negative breast cancer (TNBC). Yet, most treatment strategies focus solely on tumor cells, neglecting the immunosuppressive tumor microenvironment (TME). Given the strong correlation between TAMs infiltration and poor prognosis, innovative therapeutic strategies that modulate TAMs dynamics are urgently needed. Here, we introduce MPsomes, macrophage biomimetic nanoparticles engineered to disrupt TAMs recruitment and alter the TME. Fabricated via a microfluidic approach, MPsomes integrate macrophage membrane proteins into lipid-based nanoparticles, retaining key surface markers essential for immune interactions.

Indexed as

Antineoplastic AgentsBiomimetic MaterialsImmunotherapyNanoparticlesTriple Negative Breast NeoplasmsAnimalsCell Line, TumorCell ProliferationFemaleHumansMiceTumor MicroenvironmentAntineoplastic Agentsbiomimicryimmunotherapynanoparticlestriple-negative breast cancertumor microenvironment

Identifiers

PMID41688407
PMCPMC12961927

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.